Antimicrobial Susceptibility Testing Market worth 3.47 Billion USD by 2022

The global Antimicrobial Susceptibility Testing Market is expected to reach USD 3.47 Billion by 2022 from USD 2.71 Billion in 2017, at a CAGR of 5.1%. The major factors driving the growth of the antimicrobial susceptibility testing (AST) market include the rising prevalence of infectious diseases; increased funding, research grants, and public-private investments; and technological advancements towards rapid susceptibility testing methods.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206359984

By end user, the market is segmented into diagnostic laboratories and hospitals; pharmaceutical and biotechnology companies; contract research organizations; and research and academic institutes. The hospitals and diagnostic laboratories segment are expected to account for the largest share of the AST market in 2017 due to the increasing prevalence of infectious diseases, rising healthcare expenditure, and increasing number initiatives dedicated towards better antibiotic use. The AST market is segmented based on product into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. The manual antimicrobial susceptibility testing products segment is expected to command the largest share of the global AST market in 2017. The large share of this segment is attributed to the benefits these products offer such as low cost, ease of use, reduced labour cost, and the compatibility of manual susceptibility testing products with a wide range of organisms. Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global AST market during the forecast period (2017-2022). Factors such as the presence of prominent AST players in the region, increasing initiatives towards creating awareness about microbial resistance, and increasing healthcare expenditure are fuelling the growth of antimicrobial susceptibility testing market in this region.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206359984

The major players operating in the antimicrobial susceptibility testing market include bioMérieux (France), Danaher (US), BD (US), Thermo Fisher (US), and Bio-Rad (US), among others.

qPCR Reagents Market Development | Industry Report 2020

According to research report qPCR reagents market is poised to reach $1,893.9 Million by 2020 From USD 1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102087588

The qPCR reagents that are used for pathogen detection, forensic applications, and disease diagnosis offer a promising future to market aspirants focusing on expanding their revenue base in the market. Their growth is propelled by the increasing R&D to develop and commercialize novel products, growing market adoption of gene-based diagnostic techniques, and rising emphasis on effective & early disease diagnosis across major markets. Several companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and Takara Bio are investing in these high-growth markets to gain higher profits and to increase their shares in the global qPCR reagents market.

Thermo Fisher Scientific Inc. (U.S.) held the leadership position in the global qPCR reagents market, with a share of ~40%,. The company has a broad product portfolio for qPCR reagents, including master mixes, enzymes, nucleotides, primers, reagents, as well as consumables, among others. The company has a strong geographic presence in more than 50 countries across the globe, with key markets being the U.S., China, Germany, and the U.K. The company focuses mainly on the development of technologically advanced qPCR instruments and supporting reagents that can be used for multiple applications. In line with this strategy, Thermo Fisher Scientific has launched several qPCR reagents in the last three years, including SYBR Green master mixes and Taqman qPCR kits, among others.

North America (particularly the U.S.) is expected to hold the largest share of qPCR reagents market during the forecast period. Factors such as high penetration of qPCR technologies among key end users, increasing public & private funding to expand the application base of qPCR, ongoing product advancements in the field of qPCR reagents, and continuous reduction in the average cost of genome sequencing are driving the growth of the North American market.

On the basis of packaging type, the qPCR reagents market is classified into two major segments core kits and mastermixes. The qPCR core kits segment is expected to account for the largest share of the global market.

On the basis of end user, the market is classified into five segments hospitals and diagnostic centers, research laboratories and academic institutes, pharmaceutical and biotechnology companies, clinical research organizations, and forensic laboratories. The hospitals and diagnostic centers segment is expected to account for the largest market share of qPCR reagents market.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=102087588

Product development & commercialization, agreements, collaborations, and partnerships are the key strategies adopted by major players to strengthen their positions in the global qPCR reagents market.

Blood Gas Analyzer Market - key growth strategy adopted by major players

A number of factors, such as the growing number of patients being treated in ICUs, NICUs, and emergency departments, and the increasing adoption of technologically advanced biosensors and data analysis software for developing next-generation blood gas analyzers are expected to drive the growth of this market in the coming years.

According to the new market research Blood Gas Analyzer Market is expected to reach USD 636.0 Million by 2021, at a CAGR of 4.6% during the forecast period of 2016 to 2021.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963

Players in the blood gas analyzers market adopted organic (new product launch) as well as inorganic growth strategies (acquisitions and agreements) to increase their market shares. New product launch was the most prominent growth strategy adopted by market players between 2013 and 2016; it accounted for a share of 23.5% of the total number of strategic developments undertaken by market players in this period.

Companies such as Roche Diagnostics Limited, Nova Biomedical, Abbott Laboratories, and OPTI Medical Systems, Inc. adopted the strategy of new product launch to develop novel blood gas analyzers, strengthen their product portfolios, and address the demands of their customers. In June 2016, Roche Diagnostics launched its blood gas learning application, namely, Blood Gas Learn Your ABGs. The new app helps in learning and interpreting arterial blood gases. This enabled the company to enhance its market visibility. Similarly, Nova launched Stat Profile Prime, a blood gas analyzer, in May 2014. This testing system can be combined with Nova’s zero maintenance cartridge technology, which gives faster and accurate results. The launch of this product helped the company to expand its product offerings in the point-of-care testing market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=242278963

Several players also focused on the strategy of acquisitions to strengthen their market positions and enhance their R&D capabilities. In February 2016, Abbott entered into an agreement with Alere Inc. (a Massachusetts-based leading point-of-care diagnostics company), to acquire it for USD 5.8 billion. With this agreement, Abbott is expected to become one of the leaders in the blood gas analyzers market. ERBA-Transasia Group (India) acquired Lumora, a U.K.-based provider of patented molecular diagnostic products for the clinical and industrial markets, in September 2015. This helped the ERBA-Transasia Group to expand its product portfolio and strengthen its overall market presence.

Sterility Testing Market – Opportunities, Challenges | Global Forecast 2021

According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931

Market Dynamics:
Drivers
• Growth of pharmaceutical & biotechnology companies
• Increasing number of drug launches
• Government support for pharmaceutical and biotechnology industries
• Increasing R&D investment in life sciences
Restraints
• High degree of consolidation, major barrier for new market entrants
• Stringent regulatory frameworks and time-consuming approval processes
Opportunities
• Emerging markets
• Increasingly pharmaceutical outsourcing
Challenges
• Shortage of skilled professionals

Growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research are the key factors driving the growth of this market. The market is further driven by factors such as increasing government support for pharmaceutical and biotechnology industries.

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the sterility testing market, along with revenue estimates & forecasts and market share analysis.

Pharmaceutical and biological manufacturing
With stringent regulatory controls in place, process monitoring, and quality control are carried out for the entire production chain of pharmaceutical and biopharmaceutical products. In this process, sterility testing is carried out for raw materials, bulk lot release testing, and final product release testing.

Medical Device manufacturing
In the medical device industry, the product sterility test is necessary for ensuring that medical devices are free from viable microorganisms. Some of the important medical devices tested for sterility tests include catheters, needles, orthopedic implants, contact lenses, anesthetic and respiratory equipment, and dental implants.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931

The major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), and Thermo Fisher Scientific, Inc. (U.S.). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.

Pacemakers Market | Top Players & Business Intelligence 2023

According to research report the pacemakers market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 2.0% during the forecast period. A pacemaker is a medical device used when the heart is unable to produce electrical impulses naturally. When the heart’s natural pacemaker is defective or when the electrical pathways of the heart are blocked, it can cause irregular heartbeats, as known as arrhythmias. A pacemaker uses electrical pulses to prompt the heart to beat at a normal rate to treat arrhythmias.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243344814

• The implanted pacemakers segment, by implantability, is projected to grow at the higher CAGR during the forecast period. These devices are often placed in the chest area, just under the collarbone, to send electrical signals to start or regulate the patient’s heartbeat

• The dual-chamber pacemakers segment, by technology, is projected to grow at the highest CAGR during the forecast period. A dual-chamber pacemaker has two leads and can be external or implantable. It connects to both chambers on the right side of the heart—the right atrium and the right ventricles—and can coordinate functions between the atria and ventricles.

• The MRI compatible pacemakers segment, by type, is projected to grow at the highest CAGR during the forecast period. The development of MRI Compatible pacemakers is a major advancement in the pacemakers market. It is estimated that 75% of patients who currently have an implantable cardiac pacemaker will need MRI scans during their lifetimes.

• The hospitals & cardiac centres segment, by end user, is projected to grow at the highest CAGR during the forecast period. Factors such as the large number of cardiovascular surgical procedures performed in hospitals, improving healthcare infrastructure, and favourable reimbursement scenario are driving the growth of the pacemakers market for hospitals & cardiac centres.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=243344814

The major pacemaker’s vendors include Medtronic (Ireland), Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China). These players have adopted various growth strategies such as expansions, acquisitions, and new product launches to expand their presence in the global pacemakers market. Product launches has been the most dominating strategy adopted by major players from 2015 to 2018. This has helped them to expand their consumer base and address the unmet needs of end users.

Surgical Drains Market Development | Global Forecast 2022

According to research report the surgical drains market is expected to reach USD 2.18 Billion by 2022 from USD 1.82 Billion in 2017, growing at a CAGR of 3.7%. The growth of this market is mainly driven by the growing geriatric population, increasing number of surgical procedures, and rising awareness programs globally.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206173813

• Based on product, the market is segmented into accessories and surgical drainage systems. The surgical drainage systems segment is expected grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the growing volume of high-risk surgical procedures and the benefits associated with surgical drainage systems, such as accurate measurement of drainage, lowering bacterial levels, and effective in closing wound edges.
• Based on type, the surgical drains market is segmented into active drains and passive drains. The active drains segment is expected to register the highest CAGR during the forecast period. Advantages offered by active drains, such as efficient fluid removal and prevention from bacterial infection are supporting the growth of this market.
• Based on application, the surgical drains market is segmented into general surgery, cardiac and thoracic surgery, orthopedic surgery, obstetrics/gynecology surgery, and other surgeries. The cardiac and thoracic surgery segment is expected to register the highest CAGR during the forecast period. The high growth of this market is attributed to the large number of thoracic & cardiovascular surgeries performed across the globe owing to the high prevalence of cardiovascular diseases (CVDs).

Among the four regional segments covered in the surgical drains market—North America, Europe, Asia, and the Rest of the World (RoW), Asia is expected to grow at the highest CAGR during the forecast period. The high demand for advanced wound care and surgical care products in several Asian countries, rising geriatric population, increasing number of surgical procedures, rising prevalence of chronic as well as diabetic wounds, and focus of major players on enhancing their presence in this region are some of the key factors driving the growth of the surgical drains market in Asia.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206173813

Some of the top companies in this market include Medtronic (Ireland), B. Braun (Germany), Cardinal Health (US), Stryker (US), and Cook Medical (US).

The surgical drains market is highly competitive with several big and small players. Prominent players in this market include B. Braun (Germany), Cardinal Health (US), ConvaTec (UK), C.R. Bard (US), Redax (Italy), Ethicon (US), Stryker (US), Romsons (India), Medtronic (Ireland), Medline Industries (US), Cook Medical (US), Poly Medicure (India), Zimmer Biomet (Indiana), Global Medikit (India), Degania Silicone (Israel), Aspen Surgical (US), National Surgical (Australia), Axiom Medical (US), Péters Surgical (France), Ningbo Luke medical China), Goharshafa (Iran), ARMSTRONG MEDICAL (UK), Angiplast (India), CHIMED (Italy), and pfm medical (Germany).

Coagulation Analyzers Market Top Key Players and Global Forecast 2021

According to research report the coagulation analyzers market is projected to reach USD 4.84 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 10.2% from 2016 to 2021.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392

• Siemens AG was the largest player in the global coagulation analyzers market, with a share of 24.7% in 2015. The company has a strong presence in the U.S. and in regions such as Europe and Asia-Pacific. It focuses on product launches and agreements as its key growth strategies.
• Thermo Fisher Scientific, Inc. (U.S.) was the second-largest player in the coagulation analyzers market. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company pursues the strategies of agreements and expansions in order to increase its share in the coagulation analyzers market.
• Roche Diagnostics (Switzerland) held the third position in the global coagulation analyzers market. The company focuses on introducing innovative and technologically advanced products in the market.

The coagulation analyzers market is consolidated in nature due to the presence of a few large players. The prominent players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.).

Coagulation Analyzers Market Dynamics:
Drivers
• Increasing Prevalence of Cardiovascular Diseases and Blood Disorders
• Rising Aging Population
• Development of High-Sensitivity POC Coagulation Testing
• Increasing Laboratory Automation
Restraint
• High Cost of Fully Automated Coagulation Analyzer
Opportunities
• Emerging Markets
Challenges
• Slow Adoption of Advanced Hemostasis Instruments in Emerging Economies

This market is segmented based on product, test, technology, end-users, and regions. The coagulation analyzers market consists of various products that are used by clinical laboratories, hospitals, patient self-testing and others. Based on product, coagulation analyzers market is segmented into clinical laboratory analyzers and PoC testing analyzers. The clinical laboratory analyzers segment is expected to account for the largest share of the global coagulation analyzers market in 2016. Owing to increasing rental agreements, the consumables market is expected to grow in the coming years.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197226392